Fig. 3: β3AR agonist treatment generates endocannabinoids and N-acyl ethanolamines in the bone marrow required for MSC mobilisation. | npj Regenerative Medicine

Fig. 3: β3AR agonist treatment generates endocannabinoids and N-acyl ethanolamines in the bone marrow required for MSC mobilisation.

From: Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery

Fig. 3: β3AR agonist treatment generates endocannabinoids and N-acyl ethanolamines in the bone marrow required for MSC mobilisation.The alternative text for this image may have been generated using AI.

a Mice were pretreated with URB597 in the presence or absence of BRL37344 (β3) once daily for 4 days. 2 h after the last injection, bone marrow was collected for endocannabinoid and N-acyl ethanolamine quantification by UPLC-MS/MS; n = 18–21 mice per group with bone marrow of 3 mice pooled together for analysis. b Mice were pretreated (PT) with BRL37344 (β3) or vehicle in the presence or absence of AM251 and AM630, CB1 and CB2 antagonists (ANT), respectively, or URB597 a FAAH inhibitor as indicated once daily for 4 days. One hour after the last injection, mice were administered AMD3100 or vehicle and 1 h later blood was collected for analysis of circulating CFU-Fs; n = 8 mice per group. CFU-Fs are shown as colonies per ml of blood. a–b Data of at least two independent experiments represented as mean ± s.e.m; *P < 0.05, ***P < 0.001; NS not significant. (a Student’s t-test and b one-way ANOVA with Bonferroni correction).

Back to article page